# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(...
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's...
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Akero Therapeutics (NASDAQ:AKRO) with a Overweight.
Wolfe Research analyst Andy Chen initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Outperform rating.
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serio...
HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.